1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin 68, 394–424 (2018).
2. Cancer Registry and Statistics. Cancer Information Service, National Cancer Center,
Japan (Ministry of Health, Labour and Welfare, National Cancer Registry).
3. Tachimori Y, Ozawa S, Numasaki H, Ishihara R, Matsubara H, Muro K, Oyama T,
Toh Y, Udagawa H, Uno T; Registration Committee for Esophageal Cancer of the Japan Esophageal Society. Comprehensive registry of esophageal cancer in Japan,
2012. Esophagus 16, 221–245 (2019).
4. Domper Arnal MJ, Ferrández Arenas Á, Lanas Arbeloa Á. Esophageal cancer: Risk
factors, screening and endoscopic treatment in Western and Eastern countries. World
J Gastroenterol 21, 7933–7943 (2015).
5. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 65, 87–108 (2015).
6. Arnold M, Soerjomataram I, Ferlay J, Forman D. Global incidence of oesophageal
cancer by histological subtype in 2012. Gut 64, 381–387 (2015).
111
7. Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, Nakamura T, Yabusaki
H, Aoyama N, Kurita A, Ikeda K, Kanda T, Tsujinaka T, Nakamura K, Fukuda H. A
Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin
and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907). Ann Surg Oncol 19,
68–74 (2012).
8. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1–10 (2013).
9. Horton BL, Fessenden TB, Spranger S. Tissue Site and the Cancer Immunity Cycle.
Trends Cancer 5, 593–603 (2019).
10.
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy.
Nat Rev Cancer 12, 252–264 (2012).
11.
Hiniker SM, Chen DS, Reddy S, Chang DT, Jones JC, Mollick JA, Swetter SM,
Knox SJ. A Systemic Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy. Translational Oncology 5, 404–407 (2012).
12.
Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) path-
way to activate anti-tumor immunity. Curr Opin Immunol 24, 207–212 (2012).
112
13.
Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1 and SHP-2 As-
sociate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1
upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell
Activation. The Journal of Immunology 173, 945–954 (2004).
14.
Sznol M, Kluger HM, Hodi FS, McDermott DF, Carvajal RD, Topalian DP, At-
kins MB, Powderly JD, Sharfman WH, Puzanov I, Smith DC, Wigginton JM, Kollia
G, Gupta AK, Sosman JA.Survival and long-term follow-up of safety and response in
patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (antiPD-1; BMS-936558; ONO-4538). JCO 31, CRA9006–CRA9006 (2013).
15.
Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Her-
sey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua
AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC,
Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A. Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma. New England Journal of
Medicine 369, 134–144 (2013).
16.
Shah MA, Kojima T, Hochhauser D, Enzinger P, Raimbourg J, Hollebecque A,
Lordick F, Kim SB, Tajika M, Kim HT, Lockhart AC, Arkenau HT, El-Hajbi F, Gupta
M, Pfeiffer P, Liu Q, Lunceford J, Kang SP, Bhagia P, Kato K. Efficacy and Safety of
113
Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE180 Study. JAMA Oncol 5, 546–550 (2019).
17.
Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoim-
munity. Immunol Rev 236, 219–242 (2010).
18.
Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, An-
tonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Arén
Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L,
Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 373,
123–135 (2015).
19.
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF,
Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia
SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM,
McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia
GD, Gupta A, Wigginton JM, Sznol M. Safety, activity, and immune correlates of
anti-PD-1 antibody in cancer. N Engl J Med 366, 2443–2454 (2012).
114
20.
Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman
JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP,
Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen
DS, Hodi FS. Predictive correlates of response to the anti-PD-L1 antibody
MPDL3280A in cancer patients. Nature 515, 563–567 (2014).
21.
Tsao MS, Le Teuff G, Shepherd FA, Landais C, Hainaut P, Filipits M, Pirker R,
Le Chevalier T, Graziano S, Kratze R, Soria JC, Pignon JP, Seymour L, Brambilla E.
PD-L1 protein expression assessed by immunohistochemistry is neither prognostic
nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung
cancer. Annals of Oncology 28, 882–889 (2017).
22.
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA,
Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment
analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545–15550 (2005).
23.
Evsikov AV, Solter D. Comment on ‘ “Stemness”: Transcriptional Profiling of
Embryonic and Adult Stem Cells’ and ‘A Stem Cell Molecular Signature’ (II). Science 302, 393–393 (2003).
115
24.
Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, An-
gell H, Fredriksen T, Lafontaine L, Berger A, Bruneval P, Fridman WH, Becker C,
Pagès F, Speicher MR, Trajanoski Z, Galon J. Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer. Immunity
39, 782–795 (2013).
25.
Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D,
Hackl H, Trajanoski Z. Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade.
Cell Reports 18, 248–262 (2017).
26.
Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmie-
lowski B, Spasic M, Henry G, Ciobanu V, West AN, Carmona M, Kivork C, Seja E,
Cherry G, Gutierrez AJ, Grogan TR, Mateus C, Tomasic G, Glaspy JA, Emerson RO,
Robins H, Pierce RH, Elashoff DA, Robert C, Ribas A. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571 (2014).
27.
Pagès F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, Lagorce
C, Wind P, Marliot F, Bruneval P, Zatloukal K, Trajanoski Z, Berger A, Fridman WH,
Galon J. In situ cytotoxic and memory T cells predict outcome in patients with earlystage colorectal cancer. J Clin Oncol 27, 5944–5951 (2009).
116
28.
Bindea G, Mlecnik B, Fridman WH, Pagès F, Galon J. Natural immunity to can-
cer in humans. Current Opinion in Immunology 22, 215–222 (2010).
29.
Sharma P, Allison JP. The future of immune checkpoint therapy. Science 348,
56–61 (2015).
30.
Harris BH, Barberis A, West CM, Buffa FM. Gene Expression Signatures as Bi-
omarkers of Tumour Hypoxia. Clinical Oncology 27, 547–560 (2015).
31.
Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling tumor
infiltrating immune cells with CIBERSORT. Methods Mol Biol 1711, 243–259
(2018).
32.
Yoshihara K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, Torres-Garcia
W, Treviño V, Shen H, Laird PW, Levine DA, Carter SL, Getz G, Stemke-Hale K,
Mills GB, Verhaak RG. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun 4, 2612 (2013).
33.
Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn
M, Alizadeh AA. Robust enumeration of cell subsets from tissue expression profiles.
Nat Methods 12, 453–457 (2015).
34.
Henze AT, Mazzone M. The impact of hypoxia on tumor-associated macro-
phages. J Clin Invest 126, 3672–3679 (2016).
117
35.
Ostuni R, Kratochvill F, Murray PJ, Natoli G. Macrophages and cancer: from
mechanisms to therapeutic implications. Trends Immunol 36, 229–239 (2015).
36.
Ohno S, Ohno Y, Suzuki N, Kamei T, Koike K, Inagawa H, Kohchi C, Soma G,
Inoue M. Correlation of histological localization of tumor-associated macrophages
with clinicopathological features in endometrial cancer. Anticancer Res 24, 3335–
3342 (2004).
37.
Peng J, Zhang L, Drysdale L, Fong GH. The transcription factor EPAS-1/hy-
poxia-inducible factor 2α plays an important role in vascular remodeling. PNAS 97,
8386–8391 (2000).
38.
CDH5 cadherin 5 [Homo sapiens (human)] - Gene - NCBI.
https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=ShowDetailView&TermToSear
ch=1003.
39.
Rademakers SE, Lok J, van der Kogel AJ, Bussink J, Kaanders JH. Metabolic
markers in relation to hypoxia; staining patterns and colocalization of pimonidazole,
HIF-1α, CAIX, LDH-5, GLUT-1, MCT1 and MCT4. BMC Cancer 11, 167 (2011).
40.
Shao F, Yang X, Wang W, Wang J, Guo W, Feng X, Shi S, Xue Q, Gao S, Gao Y,
Lu Z, He J. Associations of PGK1 promoter hypomethylation and PGK1-mediated
118
PDHK1 phosphorylation with cancer stage and prognosis: a TCGA pan-cancer analysis. Cancer Commun 39, 54 (2019).
41.
Teng R, Wang Y, Lv N, Zhang D, Williamson RA, Lei L, Chen P, Lei L, Wang
B, Fu J, Liu X, He A, O'Dwyer M, Hu J. Hypoxia Impairs NK Cell Cytotoxicity
through SHP-1-Mediated Attenuation of STAT3 and ERK Signaling Pathways. J Immunol Res 2020, 4598476 (2020).
42.
Mazure NM, Pouysségur J. Atypical BH3-domains of BNIP3 and BNIP3L lead
to autophagy in hypoxia. Autophagy 5, 868–869 (2009).
43.
Sethumadhavan S, Silva M, Philbrook P, Nguyen T, Hatfield SM, Ohta A,
Sitkovsky MV. Hypoxia and hypoxia-inducible factor (HIF) downregulate antigenpresenting MHC class I molecules limiting tumor cell recognition by T cells. PLoS
One 12, e0187314 (2017).
44.
Murthy A, Gerber SA, Koch CJ, Lord EM. Intratumoral Hypoxia Reduces IFN-
γ-Mediated Immunity and MHC Class I Induction in a Preclinical Tumor Model. Immunohorizons 3, 149–160 (2019).
45.
Elia AR, Cappello P, Puppo M, Fraone T, Vanni C, Eva A, Musso T, Novelli F,
Varesio L, Giovarelli M. Human dendritic cells differentiated in hypoxia down-
119
modulate antigen uptake and change their chemokine expression profile. J Leukoc
Biol 84, 1472–1482 (2008).
46.
Mancino A, Schioppa T, Larghi P, Pasqualini F, Nebuloni M, Chen IH, Sozzani
S, Austyn JM, Mantovani A, Sica A. Divergent effects of hypoxia on dendritic cell
functions. Blood 112, 3723–3734 (2008).
47.
Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang LP, Gimotty
PA, Gilks CB, Lal P, Zhang L, Coukos G. Tumour hypoxia promotes tolerance and
angiogenesis via CCL28 and T(reg) cells. Nature 475, 226–230 (2011).
48.
Yang M, Ma C, Liu S, Sun J, Shao Q, Gao W, Zhang Y, Li Z, Xie Q, Dong Z, Qu
X. Hypoxia skews dendritic cells to a T helper type 2-stimulating phenotype and promotes tumour cell migration by dendritic cell-derived osteopontin. Immunology 128,
e237-249 (2009).
49.
Ohta A, Gorelik E, Prasad SJ, Ronchese F, Lukashev D, Wong MK, Huang X,
Caldwell S, Liu K, Smith P, Chen JF, Jackson EK, Apasov S, Abrams S, Sitkovsky
M. A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad
Sci U S A 103, 13132–13137 (2006).
50.
Caldwell CC, Kojima H, Lukashev D, Armstrong J, Farber M, Apasov SG,
Sitkovsky MV. Differential effects of physiologically relevant hypoxic conditions on
120
T lymphocyte development and effector functions. J Immunol 167, 6140–6149
(2001).
51.
Kurachi M. CD8+ T cell exhaustion. Semin Immunopathol 41, 327–337 (2019).
52.
Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman
GJ, Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439, 682–687 (2006).
53.
Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion.
Nat Rev Immunol 15, 486–499 (2015).
54.
Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL,
Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, Smylie M, Dummer R, Hill A,
Hogg D, Haanen J, Carlino MS, Bechter O, Maio M, Marquez-Rodas I, Guidoboni
M, McArthur G, Lebbé C, Ascierto PA, Long GV, Cebon J, Sosman J, Postow MA,
Callahan MK, Walker D, Rollin L, Bhore R, Hodi FS, Larkin J. Overall Survival with
Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med 377,
1345–1356 (2017).
55.
Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM,
Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg
SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q,
121
Korman AJ, Wigginton JM, Gupta A, Sznol M. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369, 122–133 (2013).
56.
Najafi M, Hashemi Goradel N, Farhood B, Salehi E, Nashtaei MS, Khanlarkhani
N, Khezri Z, Majidpoor J, Abouzaripour M, Habibi M, Kashani IR, Mortezaee K.
Macrophage polarity in cancer: A review. Journal of Cellular Biochemistry 120,
2756–2765 (2019).
57.
Liu J, Li C, Zhang L, Liu K, Jiang X, Wang X, Yang L, Liang W, Liu K, Hu J, Li
F. Association of tumour-associated macrophages with cancer cell EMT, invasion,
and metastasis of Kazakh oesophageal squamous cell cancer. Diagn Pathol 14, 55
(2019).
58.
Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and
metastasis. Cell 141, 39–51 (2010).
59.
Cao W, Peters JH, Nieman D, Sharma M, Watson T, Yu J. Macrophage subtype
predicts lymph node metastasis in oesophageal adenocarcinoma and promotes cancer
cell invasion in vitro. British Journal of Cancer 113, 738–746 (2015).
60.
Shigeoka M, Urakawa N, Nakamura T, Nishio M, Watajima T, Kuroda D,
Komori T, Kakeji Y, Semba S, Yokozaki H. Tumor associated macrophage expressing
122
CD204 is associated with tumor aggressiveness of esophageal squamous cell carcinoma. Cancer Science 104, 1112–1119 (2013).
61.
Ruffell B, Coussens LM. Macrophages and therapeutic resistance in cancer.
Cancer Cell 27, 462–472 (2015).
62.
Yin Z, Ma T, Lin Y, Lu X, Zhang C, Chen S, Jian Z. IL-6/STAT3 pathway inter-
mediates M1/M2 macrophage polarization during the development of hepatocellular
carcinoma. J Cell Biochem 119, 9419–9432 (2018).
63.
Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, Santo-
suosso M, Martin JD, Martin MR, Vianello F, Leblanc P, Munn LL, Huang P, Duda
DG, Fukumura D, Jain RK, Poznansky MC. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A 109, 17561–17566 (2012).
64.
Honkanen HK, Izzi V, Petäistö T, Holopainen T, Harjunen V, Pihlajaniemi T,
Alitalo K, Heljasvaara R. Elevated VEGF-D Modulates Tumor Inflammation and Reduces the Growth of Carcinogen-Induced Skin Tumors. Neoplasia 18, 436–446
(2016).
123
65.
Mao Y, Feng Q, Zheng P, Yang L, Zhu D, Chang W, Ji M, He G, Xu J. Low tu-
mor infiltrating mast cell density confers prognostic benefit and reflects immunoactivation in colorectal cancer. Int J Cancer 143, 2271–2280 (2018).
66.
Malfettone A, Silvestris N, Saponaro C, Ranieri G, Russo A, Caruso S, Popescu
O, Simone G, Paradiso A, Mangia A. High density of tryptase-positive mast cells in
human colorectal cancer: a poor prognostic factor related to protease-activated receptor 2 expression. J Cell Mol Med 17, 1025–1037 (2013).
67.
Saeterdal I, Bjørheim J, Lislerud K, Gjertsen MK, Bukholm IK, Olsen OC,
Nesland JM, Eriksen JA, Møller M, Lindblom A, Gaudernack G. Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc Natl Acad Sci U S A 98, 13255–13260 (2001).
68.
Colli LM, Machiela MJ, Myers TA, Jessop L, Yu K, Chanock SJ. Burden of
Nonsynonymous Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses. Cancer Res 76, 3767–3772 (2016).
69.
Cancer Genome Atlas Research Network; Analysis Working Group: Asan Uni-
versity; BC Cancer Agency; Brigham and Women’s Hospital; Broad Institute; Brown
University; Case Western Reserve University; Dana-Farber Cancer Institute; Duke
University; Greater Poland Cancer Centre; Harvard Medical School; Institute for
124
Systems Biology; KU Leuven; Mayo Clinic; Memorial Sloan Kettering Cancer Center; National Cancer Institute; Nationwide Children’s Hospital; Stanford University;
University of Alabama; University of Michigan; University of North Carolina; University of Pittsburgh; University of Rochester; University of Southern California;
University of Texas MD Anderson Cancer Center; University of Washington; Van
Andel Research Institute; Vanderbilt University; Washington University; Genome Sequencing Center: Broad Institute; Washington University in St. Louis; Genome Characterization Centers: BC Cancer Agency; Broad Institute; Harvard Medical School;
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University; University of North Carolina; University of Southern California Epigenome Center; University of Texas MD Anderson Cancer Center; Van Andel Research Institute; Genome
Data Analysis Centers: Broad Institute; Brown University:; Harvard Medical School;
Institute for Systems Biology; Memorial Sloan Kettering Cancer Center; University
of California Santa Cruz; University of Texas MD Anderson Cancer Center; Biospecimen Core Resource: International Genomics Consortium; Research Institute at Nationwide Children’s Hospital; Tissue Source Sites: Analytic Biologic Services; Asan
Medical Center; Asterand Bioscience; Barretos Cancer Hospital; BioreclamationIVT;
Botkin Municipal Clinic; Chonnam National University Medical School; Christiana
125
Care Health System; Cureline; Duke University; Emory University; Erasmus University; Indiana University School of Medicine; Institute of Oncology of Moldova; International Genomics Consortium; Invidumed; Israelitisches Krankenhaus Hamburg;
Keimyung University School of Medicine; Memorial Sloan Kettering Cancer Center;
National Cancer Center Goyang; Ontario Tumour Bank; Peter MacCallum Cancer
Centre; Pusan National University Medical School; Ribeirão Preto Medical School;
St. Joseph’s Hospital &Medical Center; St. Petersburg Academic University; Tayside
Tissue Bank; University of Dundee; University of Kansas Medical Center; University
of Michigan; University of North Carolina at Chapel Hill; University of Pittsburgh
School of Medicine; University of Texas MD Anderson Cancer Center; Disease
Working Group: Duke University; Memorial Sloan Kettering Cancer Center; National Cancer Institute; University of Texas MD Anderson Cancer Center; Yonsei
University College of Medicine; Data Coordination Center: CSRA Inc.; Project
Team: National Institutes of Health. Integrated genomic characterization of oesophageal carcinoma. Nature 541, 169–175 (2017).
70.
Cui Y, Chen H, Xi R, Cui H, Zhao Y, Xu E, Yan T, Lu X, Huang F, Kong P, Li Y,
Zhu X, Wang J, Zhu W, Wang J, Ma Y, Zhou Y, Guo S, Zhang L, Liu Y, Wang B, Xi
Y, Sun R, Yu X, Zhai Y, Wang F, Yang J, Yang B, Cheng C, Liu J, Song B, Li H,
126
Wang Y, Zhang Y, Cheng X, Zhan Q, Li Y, Liu Z. Whole-genome sequencing of 508
patients identifies key molecular features associated with poor prognosis in esophageal squamous cell carcinoma. Cell Res 30, 902–913 (2020).
71.
Du P, Huang P, Huang X, Li X, Feng Z, Li F, Liang S, Song Y, Stenvang J,
Brünner N, Yang H, Ou Y, Gao Q, Li L. Comprehensive genomic analysis of Oesophageal Squamous Cell Carcinoma reveals clinical relevance. Scientific Reports 7,
15324 (2017).
72.
Maleki Vareki S. High and low mutational burden tumors versus immunologi-
cally hot and cold tumors and response to immune checkpoint inhibitors. J Immunother Cancer 6, (2018).
73.
Blank CU, Haanen JB, Ribas A, Schumacher TN. CANCER IMMUNOLOGY.
The ‘cancer immunogram’. Science 352, 658–660 (2016).
74.
Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van
de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C,
Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A,
Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim
SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH,
Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A,
127
Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson
PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G,
André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J,
Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung
N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci
MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S,
Fox SB. Assessing tumor infiltrating lymphocytes in solid tumors: a practical review
for pathologists and proposal for a standardized method from the International Immuno-Oncology Biomarkers Working Group. Adv Anat Pathol 24, 235–251 (2017).
75.
Galon J, Angell HK, Bedognetti D, Marincola FM. The continuum of cancer im-
munosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 39,
11–26 (2013).
76.
Finn OJ. Cancer immunology. N Engl J Med 358, 2704–2715 (2008).
77.
Noman MZ, Hasmim M, Lequeux A, Xiao M, Duhem C, Chouaib S, Berchem
G, Janji B. Improving Cancer Immunotherapy by Targeting the Hypoxic Tumor Microenvironment: New Opportunities and Challenges. Cells 8, (2019).
128
78.
Lequeux A, Noman MZ, Xiao M, Sauvage D, Van Moer K, Viry E, Bocci I,
Hasmim M, Bosseler M, Berchem G, Janji B. Impact of hypoxic tumor microenvironment and tumor cell plasticity on the expression of immune checkpoints. Cancer
Letters 458, 13–20 (2019).
79.
Daniel SK, Sullivan KM, Labadie KP, Pillarisetty VG. Hypoxia as a barrier to
immunotherapy in pancreatic adenocarcinoma. Clin Transl Med 8, (2019).
80.
Shannon AM, Bouchier-Hayes DJ, Condron CM, Toomey D. Tumour hypoxia,
chemotherapeutic resistance and hypoxia-related therapies. Cancer Treatment Reviews 29, 297–307 (2003).
81.
Harris AL. Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer
2, 38–47 (2002).
82.
Yu T, Tang B, Sun X. Development of Inhibitors Targeting Hypoxia-Inducible
Factor 1 and 2 for Cancer Therapy. Yonsei Med J 58, 489–496 (2017).
83.
WARBURG O. On the Origin of Cancer Cells. Science 123, 309–314 (1956).
84.
Hu W, Zhang C, Wu R, Sun Y, Levine A, Feng Z. Glutaminase 2, a novel p53
target gene regulating energy metabolism and antioxidant function. Proc Natl Acad
Sci U S A 107, 7455–7460 (2010).
129
85.
Zhang C, Liu J, Liang Y, Wu R, Zhao Y, Hong X, Lin M, Yu H, Liu L, Levine
AJ, Hu W, Feng Z. Tumour-associated mutant p53 drives the Warburg effect. Nature
Communications 4, 2935 (2013).
86.
Eyler CE, Rich JN. Survival of the fittest: cancer stem cells in therapeutic re-
sistance and angiogenesis. J Clin Oncol 26, 2839–2845 (2008).
87.
Minassian LM, Cotechini T, Huitema E, Graham CH. Hypoxia-Induced Re-
sistance to Chemotherapy in Cancer. Adv Exp Med Biol 1136, 123–139 (2019).
88.
Saggar JK, Tannock IF. Chemotherapy Rescues Hypoxic Tumor Cells and In-
duces Their Reoxygenation and Repopulation—An Effect That Is Inhibited by the
Hypoxia-Activated Prodrug TH-302. Clin Cancer Res 21, 2107–2114 (2015).
89.
Li L, Qu Y, Mao M, Xiong Y, Mu D. The involvement of phosphoinositid 3-ki-
nase/Akt pathway in the activation of hypoxia-inducible factor-1alpha in the developing rat brain after hypoxia-ischemia. Brain Res 1197, 152–158 (2008).
90.
Yang XM, Wang YS, Zhang J, Li Y, Xu JF, Zhu J, Zhao W, Chu DK,
Wiedemann P. Role of PI3K/Akt and MEK/ERK in mediating hypoxia-induced expression of HIF-1alpha and VEGF in laser-induced rat choroidal neovascularization.
Invest Ophthalmol Vis Sci 50, 1873–1879 (2009).
130
91.
Karar J, Cerniglia GJ, Lindsten T, Koumenis C, Maity A. Dual PI3K/mTOR in-
hibitor NVP-BEZ235 suppresses hypoxia-inducible factor (HIF)-1α expression by
blocking protein translation and increases cell death under hypoxia. Cancer Biol Ther
13, 1102–1111 (2012).
92.
Griss J, Bauer W, Wagner C, Simon M, Chen M, Grabmeier-Pfistershammer K,
Maurer-Granofszky M, Roka F, Penz T, Bock C, Zhang G, Herlyn M, Glatz K, Läubli
H, Mertz KD, Petzelbauer P, Wiesner T, Hartl M, Pickl WF, Somasundaram R, Steinberger P, Wagner SN. B cells sustain inflammation and predict response to immune
checkpoint blockade in human melanoma. Nature Communications 10, 4186 (2019).
93.
Movahedi K, Laoui D, Gysemans C, Baeten M, Stangé G, Van den Bossche J,
Mack M, Pipeleers D, In't Veld P, De Baetselier P, Van Ginderachter JA. Different tumor microenvironments contain functionally distinct subsets of macrophages derived
from Ly6C(high) monocytes. Cancer Res 70, 5728–5739 (2010).
94.
Takeda N, O'Dea EL, Doedens A, Kim JW, Weidemann A, Stockmann C, Asa-
giri M, Simon MC, Hoffmann A, Johnson RS. Differential activation and antagonistic
function of HIF-{alpha} isoforms in macrophages are essential for NO homeostasis.
Genes Dev 24, 491–501 (2010).
131
95.
Chang CH, Qiu J, O'Sullivan D, Buck MD, Noguchi T, Curtis JD, Chen Q,
Gindin M, Gubin MM, van der Windt GJ, Tonc E, Schreiber RD, Pearce EJ, Pearce
EL. Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer
Progression. Cell 162, 1229–1241 (2015).
96.
Chen JL, Lucas JE, Schroeder T, Mori S, Wu J, Nevins J, Dewhirst M, West M,
Chi JT. The genomic analysis of lactic acidosis and acidosis response in human cancers. PLoS Genet 4, e1000293 (2008).
97.
Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, Bronte V,
Chouaib S. PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia
enhanced MDSC-mediated T cell activation. J Exp Med 211, 781–790 (2014).
98.
Köhler T, Reizis B, Johnson RS, Weighardt H, Förster I. Influence of hypoxia-
inducible factor 1α on dendritic cell differentiation and migration. Eur J Immunol 42,
1226–1236 (2012).
99.
Pauken KE, Wherry EJ. Overcoming T cell exhaustion in infection and cancer.
Trends Immunol 36, 265–276 (2015).
100.
Münz C. Autophagy Beyond Intracellular MHC Class II Antigen Presentation.
Trends Immunol 37, 755–763 (2016).
132
101.
Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, Shen S,
Kepp O, Scoazec M, Mignot G, Rello-Varona S, Tailler M, Menger L, Vacchelli E,
Galluzzi L, Ghiringhelli F, di Virgilio F, Zitvogel L, Kroemer G. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 334, 1573–1577 (2011).
102.
Skrombolas D, Frelinger JG. Challenges and developing solutions for increasing
the benefits of IL-2 treatment in tumor therapy. Expert Rev Clin Immunol 10, 207–
217 (2014).
103.
June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 117,
1466–1476 (2007).
104.
Postow MA, Callahan MK, Wolchok JD. Immune Checkpoint Blockade in Can-
cer Therapy. J Clin Oncol 33, 1974–1982 (2015).
105.
Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common
denominator approach to cancer therapy. Cancer Cell 27, 450–461 (2015).
106.
Qu HX, Zhao LP, Zhan SH, Geng CX, Xu L, Xin YN, Jiang XJ. Clinicopatho-
logical and prognostic significance of programmed cell death ligand 1 (PD-L1) expression in patients with esophageal squamous cell carcinoma: a meta-analysis. J
Thorac Dis 8, 3197–3204 (2016).
133
107.
Smyth MJ, Ngiow SF, Ribas A, Teng MW. Combination cancer immunothera-
pies tailored to the tumour microenvironment. Nat Rev Clin Oncol 13, 143–158
(2016).
108.
Zhang JQ, Hooker CM, Brock MV, Shin J, Lee S, How R, Franco N, Prevas H,
Hulbert A, Yang SC. Neoadjuvant chemoradiation therapy is beneficial for clinical
stage T2 N0 esophageal cancer patients due to inaccurate preoperative staging. Ann
Thorac Surg 93, 429–435; discussion 436-437 (2012).
109.
Verdeil G, Lawrence T, Schmitt-Verhulst AM, Auphan-Anezin N. Targeting
STAT3 and STAT5 in Tumor-Associated Immune Cells to Improve Immunotherapy.
Cancers (Basel) 11, (2019).
110.
Gulubova M, Vlaykova T. Prognostic significance of mast cell number and mi-
crovascular density for the survival of patients with primary colorectal cancer. J Gastroenterol Hepatol 24, 1265–1275 (2009).
111.
Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Ste-
phens PJ, Daniels GA, Kurzrock R. Tumor Mutational Burden as an Independent
Predictor of Response to Immunotherapy in Diverse Cancers. Mol Cancer Ther 16,
2598–2608 (2017).
134
112.
Gajewski TF, Corrales L, Williams J, Horton B, Sivan A, Spranger S. Cancer
Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T
Cell-Inflamed Tumor Microenvironment. Adv Exp Med Biol 1036, 19–31 (2017).
113.
Germano G, Lamba S, Rospo G, Barault L, Magrì A, Maione F, Russo M, Cris-
afulli G, Bartolini A, Lerda G, Siravegna G, Mussolin B, Frapolli R, Montone M,
Morano F, de Braud F, Amirouchene-Angelozzi N, Marsoni S, D'Incalci M, Orlandi
A, Giraudo E, Sartore-Bianchi A, Siena S, Pietrantonio F, Di Nicolantonio F, Bardelli
A. Inactivation of DNA repair triggers neoantigen generation and impairs tumour
growth. Nature 552, 116–120 (2017).
114.
Chiocca EA, Rabkin SD. Oncolytic viruses and their app ...
論文の公開元へ
